We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength?
Read MoreHide Full Article
Ocular Therapeutix (OCUL - Free Report) shares ended the last trading session 6.1% higher at $11.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 27.5% loss over the past four weeks.
Ocular Therapeutix’s stock price gain can be attributed to increasing investor confidence in recent pipeline developments for its lead product candidate, Axpaxli, for the treatment of wet age-related macular degeneration. Last week, the company announced its intention to submit a new drug application in the first quarter of 2026 seeking the drug’s approval for the above indication. The filing is contingent upon positive data from the ongoing phase III SOL-1 study. Axpaxli is also under investigation for diabetic retinopathy, diabetic macular edema, and other retinal diseases.
This biotechnology company is expected to post quarterly loss of $0.33 per share in its upcoming report, which represents a year-over-year change of -13.8%. Revenues are expected to be $15.1 million, down 11.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Ocular Therapeutix, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on OCUL going forward to see if this recent jump can turn into more strength down the road.
Ocular Therapeutix belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Profound Medical (PROF - Free Report) , closed the last trading session 9.1% lower at $7.62. Over the past month, PROF has returned 11%.
For Profound Medical, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.28. This represents a change of -40% from what the company reported a year ago. Profound Medical currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength?
Ocular Therapeutix (OCUL - Free Report) shares ended the last trading session 6.1% higher at $11.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 27.5% loss over the past four weeks.
Ocular Therapeutix’s stock price gain can be attributed to increasing investor confidence in recent pipeline developments for its lead product candidate, Axpaxli, for the treatment of wet age-related macular degeneration. Last week, the company announced its intention to submit a new drug application in the first quarter of 2026 seeking the drug’s approval for the above indication. The filing is contingent upon positive data from the ongoing phase III SOL-1 study. Axpaxli is also under investigation for diabetic retinopathy, diabetic macular edema, and other retinal diseases.
This biotechnology company is expected to post quarterly loss of $0.33 per share in its upcoming report, which represents a year-over-year change of -13.8%. Revenues are expected to be $15.1 million, down 11.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Ocular Therapeutix, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on OCUL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Ocular Therapeutix belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Profound Medical (PROF - Free Report) , closed the last trading session 9.1% lower at $7.62. Over the past month, PROF has returned 11%.
For Profound Medical, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.28. This represents a change of -40% from what the company reported a year ago. Profound Medical currently has a Zacks Rank of #3 (Hold).